The latest

News

ray therapeutics

Ray Therapeutics Awarded $8M CIRM Grant to Advance RTx-015 Gene Therapy for Retinitis Pigmentosa

“Retinitis pigmentosa remains a devastating condition with no approved treatments for the vast majority of patients,” said Paul Bresge, CEO & Co-Founder, Ray Therapeutics. “We are deeply grateful to CIRM for their belief in our science and their continued support of our programs. We are honored to partner with CIRM as we advance therapies that have the potential to transform the lives of patients.”

Latest news181

The Bakar ClimatEnginuity Hub, expected to open during the 2027-2028 academic year, will provide a home for entrepreneurs in the burgeoning field of climate technology. The donor-funded facility will be located on the west side of campus at the site currently occupied by University Hall. Rendering by Gensler

Bakar ClimatEnginuity Hub: Berkeley’s New Home for Climate Innovation

A new incubator on the west side of campus will provide resources and support to entrepreneurs in renewable energy and clean technology. Read post
Sampling Human apoptosis kit

Sampling Human Ships its First Kits for Cellular Analysis to Early Access Customers and Releases an App Note with BMG LABTECH

Daniel Georgiev, co-founder and chief executive officer of Sampling Human, will be speaking on applications for the technology at the SynBioBeta conference. “At Sampling Human, we recognize the great lengths scientists go to today in order to obtain high-quality single-cell data,” said Daniel Georgiev. “Our plug and play products are designed to deliver reliable solutions with higher specificity, lower cost and ease of use for measuring the growing number of specialized cells in the body." Read post
A large group of scientists point at the company's CEO

The Search for Useful Proteins: Berkeley Startup Aims To Turn Generative AI Into a Gene-Fixing Tool

AI-powered Profluent Bio released the world's first open-source, AI-generated gene editor, the Berkeley company said Monday, an effort that could help more scientists develop CRISPR medicines to fix a range of diseases. Profluent, a roughly 20-person company launched by former Salesforce researcher Ali Madani and University of Washington assistant professor Alexander Meeske, said its OpenCRISPR-1 gene editor uses a protein, which it developed with large language models, and guide RNA that shuttles a cutting protein where it needs to go. Read post
Steve Lo

What Makes a Good CEO? Steve Lo, Former Valitor CEO, Has Answers

A "mentorship mentality" shapes the trajectory of aspiring leaders. By mentoring others, leaders not only hone their technical knowledge but also practice crucial soft skills such as effective communication. Moreover, mentorship fosters a sense of community and support, enabling CEOs to cultivate a strong network. Read post
NY Times photographer Rachel Bujalski takes a photo of the Profluent team at BBH

Generative A.I. Arrives in the Gene Editing World of CRISPR

Much as ChatGPT learns to generate language by analyzing Wikipedia articles, books and chat logs, Profluent’s technology creates new gene editors after analyzing enormous amounts of biological data, including microscopic mechanisms that scientists already use to edit human DNA. Read post
Venkat Reddy, Greg Timblin, Ingrid Caton & David Moffat

Tenant Spotlight on Inapill: A Novel Approach to Interrupting Inflammation

“We hope this new oral therapeutic targeting proinflammatory immunometabolism will have 'pipeline-in-a-pill' potential,” says CEO and co-founder Greg Timblin. “Once it garners FDA approval in one inflammatory indication, it could be used in the clinic as a treatment across multiple inflammatory diseases. Perhaps it could even provide benefit to patients with more complex diseases where excessive inflammation is thought to be a driving factor, such as cardiometabolic and neurodegenerative diseases.” Read post
The East Bay Innovation award with Bakar Labs skylight in background

Bakar Labs Wins East Bay Innovation Award

The Innovation Award recognizes the real contribution Bakar Labs makes to the regional economy by supporting entrepreneurs building new companies, hiring skilled workers, bringing in investment, expanding their operations, and forging partnerships as they develop cures and solutions for the most urgent challenges that face us in human health. Since the incubator’s launch in November 2021, the 38 companies that we’ve hosted have raised more than $380 million and created more than 300 jobs. Read post
Screenshot of the Profluent homepage. "Decoding the language of life with AI"

Profluent Secures $35M in Additional Funding and Key Industry Experts to Scale Foundational AI Models for Biomedicine and Tackle First Vertical in Gene Editing

“Our research at the forefront of AI has enabled Profluent to create large language models that begin to learn the blueprint of nature,” said Ali Madani, Profluent co-founder and Chief Executive Officer. “We are moving biology from being constrained by what can be discovered in nature to being able to design precisely according to our needs via AI. The science is real and the time is now to proactively create breakthrough medicines that can transform society.” Read post